Clinical Study
Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan
Table 2
Patient characteristics.
| | Characteristics | Number of cases | % |
| | Patients | 18 | | | Median years of age (range) | 56 (38–79) | | | Gender, male/female | 5/13 | 28/72 | | ECOG PS, 0/1 | 16/2 | 89/11 | | Median body height of patients (range) | 157.5 cm (147.3–175) | | | Median body weight of patients (range) | 50.6 kg (39.9–76.5) | | | Median body surface area of patients (range) | 1.5 m2 (1.33–1.83) | | | Median quantity of administered R (range) | 560 mg (498–680) | | | Cardiac function (pretreatment) | | | | Median level of BNP (range) | 15.1 pg/mL (5.8–55.5) | | | Median % of LVEF (range) | 73% (58.3–81.8) | | | Diagnosis | | | | Follicular lymphoma (FL), grade 1 | 10 | 56 | | FL + diffuse large B-cell lymphoma | 2 | 11 | | Extranodal marginal zone lymphoma | 1 | 6 | | Nodal marginal zone lymphoma | 1 | 6 | | Waldenström’s macroglobulinemia | 1 | 6 | | Mantle cell lymphoma | 1 | 6 | | Diffuse large B-cell lymphoma | 2 | 11 | | Regimens | | | | R-CHOP | 2 | 11 | | R-CVP | 2 | 11 | | R (as maintenance therapy) | 14 | 78 | | Total cycles of R (range, for each patient) | 88 (4–8) | |
|
|
ECOG: Eastern Cooperative Oncology Group; PS: performance status; R: rituximab; BNP: brain natriuretic peptide; LVEF: left ventricular ejection fraction; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, and predonisolone; R-CVP: rituximab, cyclophosphamide, vincristine, and predonisolone.
|
